• October 17, 2019

Lipocine To Present LPCN 1144 Poster Of Distinction At The Liver Meeting® 2019 - Odessa American: Business

e-Edition Subscribe

Lipocine To Present LPCN 1144 Poster Of Distinction At The Liver Meeting® 2019

Print
Font Size:
Default font size
Larger font size

Posted: Tuesday, October 1, 2019 7:00 am | Updated: 7:47 am, Tue Oct 1, 2019.

SALT LAKE CITY, Oct. 1, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that data from a clinical trial of LPCN 1144 in non-alcoholic fatty liver disease ("NAFLD") will be presented at The Liver Meeting® 2019. The Liver Meeting® 2019, which is the annual meeting of the American Association for the Study of Liver Diseases ("AASLD"), a leading organization of scientists and healthcare professionals committed to preventing and curing liver disease, will be held on November 8th – 12th in Boston, Massachusetts. Lipocine's abstract has been selected by the Scientific Program Committee of the AASLD as a Poster of Distinction for presentation.

About Lipocine

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes TLANDO, LPCN 1144, TLANDO XR (LPCN 1111), LPCN 1148 and LPCN 1107 development programs. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men and currently under USFDA review for marketing approval. LPCN 1144, a differentiated oral product of bioidentical testosterone, is currently undergoing Phase 2 clinical testing in biopsy confirmed NASH patients and recently completed a proof-of-concept clinical study demonstrating the potential utility the in treatment of NASH. TLANDO XR (LPCN 1111), a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and has completed Phase 2 testing. LPCN 1148 is a unique oral testosterone product targeted to treat NASH cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed. For more information, please visit www.lipocine.com.

Forward-Looking Statements

This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding Lipocine's product candidates and related clinical trials, the timing of completion of clinical trials, the potential uses and benefits of our product candidates, and our product development efforts. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

View original content to download multimedia: http://www.prnewswire.com/news-releases/lipocine-to-present-lpcn-1144-poster-of-distinction-at-the-liver-meeting-2019-300927143.html

SOURCE Lipocine Inc.

© 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Clear
72°
Humidity: 27%
Winds: SE at 8mph
Feels Like: 72°

Your Extended Forecast

Tomorrow

weather
High 83°/Low 56°
Clear. Lows overnight in the mid 50s.

friday

weather
High 87°/Low 54°
Sunshine. Highs in the upper 80s and lows in the mid 50s.

saturday

weather
High 80°/Low 54°
Sunny. Highs in the low 80s and lows in the mid 50s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.